AIMS: To assess the efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes enrolled in the CANagliflozin cardioVascular Assessment Study (CANVAS) who were on an incretin mimetic (i.e. dipeptidyl peptidase-4 [DPP-4] inhibitor or glucagon-like peptide-1 [GLP-1] receptor agonist). MATERIALS AND METHODS: CANVAS is a double-blind, placebo-controlled study that randomized participants to placebo or canagliflozin 100 or 300 mg added to routine therapy. This post hoc analysis assessed efficacy and safety of canagliflozin 100 and 300 mg compared with placebo in subsets of patients from CANVAS who were taking background DPP-4 inhibitors or GLP-1 receptor agonists with or without other antihyperglycaemic agents at week 18. RESULTS: Of the 4,330 CANVAS patients, 316 were taking DPP-4 inhibitors and 95 were taking GLP-1 receptor agonists. At 18 weeks, canagliflozin 100 and 300 mg provided larger placebo-subtracted reductions (95% confidence interval) in HbA1c in patients taking DPP-4 inhibitors (-0.56% [-0.77, -0.35] and -0.75% [-0.95, -0.54], respectively) and GLP-1 receptor agonists (-1.00% [-1.35, -0.65] and -1.06% [-1.43, -0.69], respectively). Body weight and blood pressure (BP) reductions were seen with canagliflozin versus placebo in both subsets. Greater incidences of genital mycotic infections and osmotic diuresis-related adverse events (AEs) were seen with canagliflozin compared with placebo. Incidence of hypoglycaemia was numerically higher with canagliflozin versus placebo; nearly all occurred in patients on background insulin or insulin secretagogues. CONCLUSIONS: In patients on background incretin mimetics, canagliflozin improved HbA1c, body weight and BP, with an increased incidence of AEs related to SGLT2 inhibition.
AD - The Royal North Shore Hospital and University of Sydney, Sydney, Australia.AIMS: To assess the efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes enrolled in the CANagliflozin cardioVascular Assessment Study (CANVAS) who were on an incretin mimetic (i.e. dipeptidyl peptidase-4 [DPP-4] inhibitor or glucagon-like peptide-1 [GLP-1] receptor agonist). MATERIALS AND METHODS: CANVAS is a double-blind, placebo-controlled study that randomized participants to placebo or canagliflozin 100 or 300 mg added to routine therapy. This post hoc analysis assessed efficacy and safety of canagliflozin 100 and 300 mg compared with placebo in subsets of patients from CANVAS who were taking background DPP-4 inhibitors or GLP-1 receptor agonists with or without other antihyperglycaemic agents at week 18. RESULTS: Of the 4,330 CANVAS patients, 316 were taking DPP-4 inhibitors and 95 were taking GLP-1 receptor agonists. At 18 weeks, canagliflozin 100 and 300 mg provided larger placebo-subtracted reductions (95% confidence interval) in HbA1c in patients taking DPP-4 inhibitors (-0.56% [-0.77, -0.35] and -0.75% [-0.95, -0.54], respectively) and GLP-1 receptor agonists (-1.00% [-1.35, -0.65] and -1.06% [-1.43, -0.69], respectively). Body weight and blood pressure (BP) reductions were seen with canagliflozin versus placebo in both subsets. Greater incidences of genital mycotic infections and osmotic diuresis-related adverse events (AEs) were seen with canagliflozin compared with placebo. Incidence of hypoglycaemia was numerically higher with canagliflozin versus placebo; nearly all occurred in patients on background insulin or insulin secretagogues. CONCLUSIONS: In patients on background incretin mimetics, canagliflozin improved HbA1c, body weight and BP, with an increased incidence of AEs related to SGLT2 inhibition.
PY - 2015 SN - 1463-1326 (Electronic)